Login
$TGTX
$62.74 -$0.02 (0.03%) After hours

$TGTX 8-K/A SEC Filings

Filed On Filing
22 Jun 2015 8-K/A: Other Events

Updated Results from Phase 2 Clinical Trial of TG-1101 (Ublituximab) in Combination with Ibrutinib Confirms Robust Clinical Activity with a Favorable Safety Profile in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leuke...

05 May 2015 8-K/A: Results of Operations and Financial Condition

On May 4, 2015, TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release announcing results of operations for the first quarter ended March 31, 2015. TG also announced that on Tuesday, May 5, 2015 at 8:00am EDT, TG would host...

23 Sep 2014 8-K/A: Entry into a Material Definitive Agreement

On September 22, 2014, TG Therapeutics, Inc. (the “Company”) exercised its option to license (“license option”) the global rights to TGR-1202, thereby entering into an exclusive licensing agreement (the “Agreement”) with Rhizen Pharmaceu...

16 Mar 2012 8-K/A: Financial Statements and Exhibits

Consolidated Statement of Operations for the year and cumulative period ended December 31, 2011

03 Feb 2012 8-K/A: Departure/Election of Directors or Officers; Compensation

Effective December 29, 2011, Douglas Abel, David C. Shimko and Richard Steinhart resigned from their positions on the Board of Directors of the Company. Michael McGuinness resigned both his seat as a director and as an officer of the Com...

11 Mar 2011 8-K/A: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
24 May 2010 8-K/A: Completion of Acquisition or Disposition of Assets

We have audited the accompanying consolidated balance sheets of Ariston Pharmaceuticals, Inc. and subsidiary (A Development Stage Company) as of December 31, 2009 and 2008, and the related consolidated statements of operations, changes i...

19 Sep 2005 8-K/A: Unregistered Sales of Equity Securities; Other Events

Manhattan Pharmaceuticals, Inc. (the "Company") recently sold in a private placement offering (the "Offering") to accredited investors units of its securities consisting of shares of common stock ("Shares") and warrants to purchase addit...

15 Jun 2005 8-K/A: Completion of Acquisition or Disposition of Assets

This Agreement and Plan of Merger (this “Agreement”) is entered into as of April 1, 2005, by and among Manhattan Pharmaceuticals, Inc., a company duly organized and existing under the laws of the State of Delaware, having a place of busi...

09 May 2003 8-K/A: Completion of Acquisition or Disposition of Assets

Our report on our audit of the financial statements of Manhattan Pharmaceuticals, Inc. (a development stage company) as of December 31, 2001 and the related statements of operations, changes in stockholders' deficiency and cash flows for...

02 Jun 1999 8-K/A: Other Events

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ----------------------------------

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support